Ab hg fe d c Supplementary Figure 1 Supplementary figure 1: Validation of the ERRα antibody used for immunohistochemical analysis. Control MCF7 breast.

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 actin MocksiRNA1siRNA2Mock Li Fraumeni (087)5C tankyrase1 100

Advertisements

PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.

Lyn Tyrosine Kinase Regulates Androgen Receptor Expression and Activity in Castrate Resistant Prostate Cancer Anousheh Zardan, Ka Mun Nip, Daksh Thaper,

(+++) Normal breast ATM (++) IDC ATM Lymph node metastasis negative positive P-value A B X200 C Vector ATM - WT.

Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.

Figure S1. RNA-seq results for caveolin-1 (Cav1). Upper panel: UCSC genome browser view. Lower panel: quantification o f Cav1 expression based on RNA-seq.

Na + /H + exchanger regulatory factor 1 (NHERF1) and angiogenesis in familial breast cancer A Mangia*, A Malfettone*, C Salvatore**, B Stea*, G Simone**

ER  HSP90 DMSO 200  M I3C30  M DIM200  M TRYPTOPHOL Supplemental Figure 1. DIM and Tryptophol fail to induce the downregulation of ER  seen with I3C.

Supplementary Figure 1. Expression of hormone receptors in cultured T47D and MCF7 cells. A) Immunocytochemistry of estrogen receptor-α (ERα), progesterone.

Supplemental Figure 1: ER  expression in MCF-7 cells. MCF-7 cells were either pre-treated with ICI 182,780 (lanes 5-8) or EtOH (vehicle, lanes 1-4) for.

Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

Postmenopausal breast cancer patients included in the original Stockholm tamoxifen trial (n=2459) Stockholm 2 cohort (n=679) Stockholm 3 cohort (n=1780)

B Supplementary Fig S1. (A) ZR75- and MCF7-PELP1 knockdown cells were generated as described in methods section. Pooled colonies were analyzed for PELP1.

Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.

Supplementary Figure 1 Supplementary Figure 1. Kaplan–Meier estimates of recurrence-free survival (RFS) according to the expression of every ten mRNA/lncRNA.

Supplementary Figures. Figure Legends Suppl. Figure 1. Flow cytometry analysis to monitor apoptosis levels in MCF-7 cells. As control MCF-7 cells grown.

A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.

Products > SKNAS Transfection Reagent (Neuroblastoma Cells) Altogen Biosystems offers the SKNAS Transfection Reagent among a host of 100+ cell line specific.

Altogen Biosystems offers the Transfection Reagent for PANC-1 Cells Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection.

Products > 293T/17 Transfection Reagent (Embryonic Kidney Cells, CRL-11268) Altogen Biosystems offers the 293T/17 Transfection Reagent among a host of.

Products > U87 Transfection Reagent (Glioblastoma Cells) Altogen Biosystems offers the U87 Transfection Reagent among a host of 100+ cell line specific.

Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.

Altogen Biosystems offers the 786-O Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. 786-O Transfection Reagent.

Products > MCF-7 Transfection Reagent (Breast Cancer, HTB-22) Altogen Biosystems offers the MCF-7 Transfection Reagent among a host of 100+ cell line specific.

Supplementary Figure 1. Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer. (A-C) CDK7, CyclinH and MAT1 mRNA levels, determined by real-time.

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Supplementary Figure 1 A C E B D F ** untreated Anti-miR-375 * * Mtpn

High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated.

Development of Med28 Specific Monoclonal Antibodies

Neal et al.Supplementary Figure S1

Products > BT-20 Transfection Reagent (Breast Carcinoma Cells)

Figure 2. A consort diagram showing the flowchart of the trial

Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors Anita Muthukaruppan, Annette Lasham,

Figure S1. DCYTB expression is higher in ER+ than ER- patients

Targeting DNA Replication before it Starts

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

Overexpression of ornithine decarboxylase enhances endothelial proliferation by suppressing endostatin expression by Takahiro Nemoto, Hisae Hori, Masataka.

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis Diana Ramirez-Ardila, A. Mieke Timmermans,

The SCF/KIT Pathway Plays a Critical Role in the Control of Normal Human Melanocyte Homeostasis James M. Grichnik, James A. Burch, James Burchette, Christopher.

Sunny Guin, PhD, Yuanbin Ru, PhD, Murry W

Volume 134, Issue 1, Pages (January 2008)

PPARγ signaling correlates with LATS2 in human and mouse tumors and promotes cell death in a LATS2-dependent manner. PPARγ signaling correlates with LATS2.

Volume 11, Issue 2, Pages (February 2005)

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

A B Yeom Supplementary Fig.2

Katja Lundgren, Nicholas P

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with.

Volume 13, Issue 2, Pages (February 2008)

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α

COP1 Contributes to UVB-Induced Signaling in Human Keratinocytes

MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α

Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm Chenyang Dai, MD, Huikang.

Volume 20, Issue 4, Pages (October 2011)

ADAM8 is induced by hypoxia and promotes angiogenesis ASixteen h after plating, cells were cultured under normoxic (−) or hypoxic (+, 1% O2) conditions.

A, DEAR1 and SMAD3 immunohistochemical staining in human breast cancer tissues. A, DEAR1 and SMAD3 immunohistochemical staining in human breast cancer.

Time to Recurrence (Hormone Receptor-positive Patients)

Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance Xin Dong, MD, Dong Lin,

MW (kDa) 2 µg 0.5 µg Supplementary Figure S1. SDS-PAGE under reducing condition analysis (Coomassie brilliant blue staining) of.

Figure 8. Measurement of levels of apoptotic proteins

CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection of CXCR4 siRNAs. CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection.

A, TSG-6 staining in TRAMP tissue and TRAMP cell lines.

Tamoxifen-treated patients.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

a b c Supplementary Figure 1

Presentation transcript:

ab hg fe d c Supplementary Figure 1 Supplementary figure 1: Validation of the ERRα antibody used for immunohistochemical analysis. Control MCF7 breast cancer cell line (a), ERRα siRNA treated MCF7 cells (b). Representative selection of immunohistochemical staining pattern of ERRα; negative nucleus (c), strong nucleus (d), negative cytoplasm (e), strong cytoplasm (f), medium cytoplasm and medium nucleus (g), and a mix of medium and negative nuclei (h). To validate the ERRα antibody used for immunohistochemistry MCF7 cells (ATCC, LGC standards, UK) cultured in phenol-red free Optimem media supplemented with 4% FBS (Gibco by Life Technologies, UK) were transfected with control siRNA (Silencer® Negative Control No. 1; AM4611) or ERRα -directed siRNA (Ambion by Life Technologies, UK; s4829 and s4830) using the Amaxa Nucleofector system (Lonza, Swizerland; Program P-020) with the nucleofection reagent kit V. Transfected cells were harvested 72 h post-transfection, formalin fixed, dehydrated and paraffin embedded. Sections of 4µm were prepared for immunohistological staining according to the protocol used for TMAs.

ER- Cytoplasmic ERRαNuclear ERRα AB HR (BCS): 1.46 ( ) HR (RFS): 1.08 ( ) HR (BCS): 2.94 ( ) HR (RFS): 1.73 ( ) Adjuvant untreated Supplementary Figure 2 Supplementary Figure 2: The prognostic value of ERRα protein expression and subcellular location in adjuvant-untreated ER-negative patients. The prognostic value of ERRα levels evaluated according to hormone receptor status in adjuvant untreated patients (A- B). Breast cancer survival (BCS), Hazard ratio (HR); (95% confidence interval).

ER+ Cytoplasmic ERRαNuclear ERRα HR (BCS): 1.46 ( ) HR (RFS): 1.27 ( ) RFS, HR: 0.76 ( ), p=0.31 MFS, HR: 0.81 ( ), p=0.50 BCS, HR: 0.93 ( ), p=0.85 HR (BCS): 0.98 ( ) HR (RFS): 1.18 ( ) RFS, HR: 0.86 ( ), p=0.58 MFS, HR: 0.93 ( ), p=0.82 BCS, HR: 1.32 ( ), p=0.48 Adjuvant untreated Tamoxifen treated A C B D Supplementary Figure 3 Supplementary Figure 3: ERRα protein expression is not prognostic in ER-positive breast cancer. The prognostic value of ERRα levels evaluated according to hormone receptor status in adjuvant untreated patients (A, C), and in tamoxifen-treated patients (B, D). Breast cancer survival (BCS), Recurrence-free survival (RFS), Metastasis-free survival (MFS), Hazard ratio (HR); (95% confidence interval).